Cosmo Pharmaceuticals N.V. (SWX:COPN)
115.80
+1.20 (1.05%)
At close: Jan 30, 2026
Cosmo Pharmaceuticals Revenue
Cosmo Pharmaceuticals had revenue of 51.72M EUR in the half year ending June 30, 2025, with 18.46% growth. This brings the company's revenue in the last twelve months to 182.27M, down -1.66% year-over-year. In the year 2024, Cosmo Pharmaceuticals had annual revenue of 266.79M with 187.55% growth.
Revenue (ttm)
182.27M EUR
Revenue Growth
-1.66%
P/S Ratio
10.84
Revenue / Employee
549.01K EUR
Employees
332
Market Cap
1.85B CHF
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.79M | 174.01M | 187.55% |
| Dec 31, 2023 | 92.78M | -9.31M | -9.12% |
| Dec 31, 2022 | 102.09M | 37.02M | 56.88% |
| Dec 31, 2021 | 65.07M | 4.13M | 6.77% |
| Dec 31, 2020 | 60.95M | -1.55M | -2.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 3.73B |
| Aevis Victoria | 955.96M |
| Tecan Group AG | 906.60M |
| Medacta Group | 603.41M |
| PolyPeptide Group AG | 344.49M |
Cosmo Pharmaceuticals News
- 19 days ago - Cosmo Pharmaceuticals Posts EUR 104 Mln Revenue, Midpoint Of 2025 Guidance Range - Nasdaq
- 7 weeks ago - Is this the end of baldness? This stock jumps 50% on breakthrough - Finbold
- 2 months ago - Cosmo Pharmaceuticals (CMOPF) Stock Soars on Promising Hair Loss Treatment Results - GuruFocus
- 2 months ago - EU Grants Marketing Authorization For Winlevi Cream - Nasdaq
- 3 months ago - EU Approves Cosmo Pharma' Winlevi For Acne Treatment In Adults And Adolescents - Nasdaq
- 5 months ago - Winlevi Acne Cream Secures EU Drug Panel Support in Reversal for Cosmo - Financial Post
- 10 months ago - Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel - Cash
- 11 months ago - Cosmo Pharmaceuticals reports FY results - Seeking Alpha